{
  "PMC5508045": {
    "rs9923231": [
      "The patients with variant genotypes of VKORC1 \u2212 1639G > A required significantly lower warfarin stable weekly doses (SWDs) than those with wild-type genotype (p < 0.001).",
      "Patients with AA and GA genotypes of VKORC1 \u2212 1639G > A required 49.7% and 27.7% significantly lower averages of SWDS of warfarin as compared with those with wild-type GG genotype (p < 0.001).",
      "## Table 2: Differences in stable weekly doses of warfarin among genotypes"
    ],
    "rs1057910": [
      "Similarly, the patients with CYP2C9*3 variant allele required significantly lower warfarin SWDs than those with homozygous wild-type (p = 0.006).",
      "The warfarin SWDs were decreased by 7.9 mg and 25.9 mg in the patients with CYP2C9 *1/*3* and *CYP2C9 *3/*3* genotypes as compared with those with wild-type *1/*1* genotype (p < 0.001).",
      "## Table 2: Differences in stable weekly doses of warfarin among genotypes"
    ],
    "rs2108622": [
      "Multivariate analysis, however, showed that CYP4F2 rs2108622 TT genotype accounted for a modest part of warfarin dose variability (1.2%).",
      "For co-medications, warfarin SWDs were increased by 4.1 mg in the patients with the TT variant genotype of CYP4F2 rs2108622 as compared with those with the wild-type CC genotype (p = 0.016).",
      "## Table 3: Multiple linear regression analyses for variables responsible for stable weekly warfarin doses"
    ],
    "rs887829": [
      "In contrast, there were no significant differences in the SWDs between the patients who carried variant alleles of CYP4F2 rs2108622 and UGT1A1 rs887829 as compared to wild-type allele carriers.",
      "The present results showed that UGT1A1 rs887829 did not significantly contribute to the variability of the stable warfarin doses (Table 2).",
      "## Table 2: Differences in stable weekly doses of warfarin among genotypes"
    ]
  },
  "PMC4916189": {
    "CYP2B6*1": [
      "Discontinuation due to adverse events (clinician decision) was independently associated with dose (OR 2.54, 95 % CI 1.19\u20135.43, p = 0.016).",
      "Possession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively), whereas NR1I2 63396TT carriers were at decreased risk (22 %).",
      "## Table 4: Cox regression assessing the relationship between overall discontinuation of efavirenz once daily and CYP2B6, CYP2A6, CYP3A4, ABCB1, NR1I3, NR1I2 polymorphisms"
    ],
    "CYP2B6*9": [
      "Discontinuation due to adverse events (clinician decision) was independently associated with dose (OR 2.54, 95 % CI 1.19\u20135.43, p = 0.016).",
      "Possession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively), whereas NR1I2 63396TT carriers were at decreased risk (22 %).",
      "## Table 4: Cox regression assessing the relationship between overall discontinuation of efavirenz once daily and CYP2B6, CYP2A6, CYP3A4, ABCB1, NR1I3, NR1I2 polymorphisms"
    ],
    "rs3745274": [
      "Possession of the CYP2B6 516GT and TT variants and CYP2A6*9B CA/AA carriers was associated with a higher risk of overall EFV discontinuation (80, 166 and 100 %, respectively), whereas NR1I2 63396TT carriers were at decreased risk (22 %).",
      "Discontinuation due to adverse events (clinician decision) was independently associated with dose (OR 2.54, 95 % CI 1.19\u20135.43, p = 0.016).",
      "## Table 4: Cox regression assessing the relationship between overall discontinuation of efavirenz once daily and CYP2B6, CYP2A6, CYP3A4, ABCB1, NR1I3, NR1I2 polymorphisms"
    ],
    "rs2472677": [
      "A decreased risk of CNS adverse events (Stocrin\u00ae product information) was associated with CYP2B6 983TC or CC carriers (OR 0.30, 95 % CI 0.12\u20130.75, p = 0.010) but an increased risk in patients with CYP2B6 15582CT or TT and ABCB1 3435TT carriers was observed (OR 1.59, 95 % CI 1.11\u20132.27, p = 0.011; and OR 2.14, 95 % CI 1.25\u20133.67, p = 0.006, respectively).",
      "## Table 4: Cox regression assessing the relationship between overall discontinuation of efavirenz once daily and CYP2B6, CYP2A6, CYP3A4, ABCB1, NR1I3, NR1I2 polymorphisms",
      "A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed."
    ],
    "rs1045642": [
      "Lower risk of CNS-related adverse events was associated with CYP2B6 983TC/CC (OR 0.35, 95 % CI 0.15\u20130.81, p = 0.015) and higher risk was associated with CYP2B6 15582CT/TT and ABCB1 3435TT (OR 1.46, 95 % CI 1.02\u20132.09, p = 0.040; OR 2.31, 95 % CI 1.33\u20134.02, p = 0.003, respectively).",
      "A decreased risk of CNS adverse events (Stocrin\u00ae product information) was associated with CYP2B6 983TC or CC carriers (OR 0.30, 95 % CI 0.12\u20130.75, p = 0.010) but an increased risk in patients with CYP2B6 15582CT or TT and ABCB1 3435TT carriers was observed (OR 1.59, 95 % CI 1.11\u20132.27, p = 0.011; and OR 2.14, 95 % CI 1.25\u20133.67, p = 0.006, respectively).",
      "## Table 4: Cox regression assessing the relationship between overall discontinuation of efavirenz once daily and CYP2B6, CYP2A6, CYP3A4, ABCB1, NR1I3, NR1I2 polymorphisms"
    ],
    "rs28399499": [
      "A decreased risk of CNS adverse events (Stocrin\u00ae product information) was associated with CYP2B6 983TC or CC carriers (OR 0.30, 95 % CI 0.12\u20130.75, p = 0.010) but an increased risk in patients with CYP2B6 15582CT or TT and ABCB1 3435TT carriers was observed (OR 1.59, 95 % CI 1.11\u20132.27, p = 0.011; and OR 2.14, 95 % CI 1.25\u20133.67, p = 0.006, respectively).",
      "## Table 4: Cox regression assessing the relationship between overall discontinuation of efavirenz once daily and CYP2B6, CYP2A6, CYP3A4, ABCB1, NR1I3, NR1I2 polymorphisms",
      "A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed."
    ],
    "rs4803419": [
      "A decreased risk of CNS adverse events (Stocrin\u00ae product information) was associated with CYP2B6 983TC or CC carriers (OR 0.30, 95 % CI 0.12\u20130.75, p = 0.010) but an increased risk in patients with CYP2B6 15582CT or TT and ABCB1 3435TT carriers was observed (OR 1.59, 95 % CI 1.11\u20132.27, p = 0.011; and OR 2.14, 95 % CI 1.25\u20133.67, p = 0.006, respectively).",
      "## Table 4: Cox regression assessing the relationship between overall discontinuation of efavirenz once daily and CYP2B6, CYP2A6, CYP3A4, ABCB1, NR1I3, NR1I2 polymorphisms",
      "A higher rate of EFV-related adverse events and discontinuations due to these events for EFV600 were not driven by polymorphisms assessed."
    ]
  },
  "PMC12036300": {
    "CYP2C19*1": [
      "No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.",
      "In Syrian patients undergoing PCI, a doubled maintenance dose of clopidogrel (150 mg/day) may help mitigate variability in response due to CYP2C19*2 carrier status, offering potential benefits in optimizing antiplatelet therapy.",
      "The present study did not confirm an association between MACE incidence and the carrier status of the non-functional CYP2C19*2 allele, which has been established in many previous studies and meta-analyses."
    ],
    "CYP2C19*2": [
      "No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.",
      "In Syrian patients undergoing PCI, a doubled maintenance dose of clopidogrel (150 mg/day) may help mitigate variability in response due to CYP2C19*2 carrier status, offering potential benefits in optimizing antiplatelet therapy.",
      "The present study did not confirm an association between MACE incidence and the carrier status of the non-functional CYP2C19*2 allele, which has been established in many previous studies and meta-analyses."
    ],
    "CYP2C19*17": [
      "No association was found between the CYP2C19*2 allele and recurrent ischemic events or between the CYP2C19*17 allele and bleeding complications in patients treated with a doubled maintenance dose of clopidogrel.",
      "In Syrian patients undergoing PCI, a doubled maintenance dose of clopidogrel (150 mg/day) may help mitigate variability in response due to CYP2C19*2 carrier status, offering potential benefits in optimizing antiplatelet therapy.",
      "The present study did not confirm an association between MACE incidence and the carrier status of the non-functional CYP2C19*2 allele, which has been established in many previous studies and meta-analyses."
    ]
  }
}